MIRM 财报电话会议

MIRM will achieve positive adjusted EBITDA (excluding stock-based compensation and one-time charges) by end of next fiscal quarter, demonstrating core business profitability milestone.

MIRM's R&D expense as a percentage of revenue will decline to below 65% within the next three reported quarters, indicating successful transition from development-stage to commercial-stage company operations.

MIRM's operating cash flow will increase by at least 40% year-over-year in the next two quarters, reflecting improved working capital management and reduced R&D spending intensity as pipeline programs advance toward commercialization.

MIRM's gross margin will expand by at least 300 basis points year-over-year in the next reported quarter, indicating improved manufacturing efficiency and product mix optimization from pipeline progression.

MIRM will report sequential revenue growth of at least 25% in the quarter following the earnings call, driven by increased commercial uptake of approved indications mentioned in guidance.

Mirum Pharma's MIRM stock price will outperform the broader pharma sector (XBI) by at least 15% within 90 days following positive Phase 3 trial data disclosure in the earnings call regarding their lead candidate.